Aurinia Pharmaceuticals Inc. ( AUPH) Stock. Should you Buy or Sell? $ 7.26
0.44 (5.71 %)
Aurinia Pharmaceuticals Inc. Analysis
Updated on 10-09-2022| Symbol | AUPH |
| Price | $7.26 |
| Beta | 0.942 |
| Volume Avg. | $2.81 M |
| Market Cap | $1.03 B |
| 52 Week Range | $6.28 - $33.972 |
Aurinia Pharmaceuticals Inc. opened the day at $7.26 which is +'5.71 % on yesterday's close. Aurinia Pharmaceuticals Inc. has a 52 week high of $33.972 and 52 week low of $6.28, which is a difference of $27.692. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $1.03 B and total net profit is $45605000 which means the company is trading at 22.59 times profit to market capitalization. Theoretically, if you were to buy Aurinia Pharmaceuticals Inc. for $1.03 B, it would take 15 years to get your money back. Aurinia Pharmaceuticals Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Aurinia Pharmaceuticals Inc. Stock Forecast - Is Aurinia Pharmaceuticals Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -6.581 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -1.783 |
Valuing Aurinia Pharmaceuticals Inc.
| Price Book Value Ratio | 2.434 | Price To Book Ratio | 2.434 |
| Price To Sales Ratio | 11.735 | Price Earnings Ratio | -6.581 |
How liquid is Aurinia Pharmaceuticals Inc.
| Current Ratio | 13.088 |
| Quick Ratio | 11.838 |
Debt
| Debt Ratio | 0.121 | Debt Equity Ratio | 0.138 |
| Long Term Debt To Capitalization | 0.017 | Total Debt To Capitalization | 0.019 |
Latest news about Aurinia Pharmaceuticals Inc.
LUPKYNIS revenues and company net losses are tracking better than my valuation model predicts -- and new European revenues are on the horizon. However, expenses continue to rise, which is contrary to my modelling.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants DeDe Sheel – Vice President-Investor Relations Peter Greenleaf – President and Chief Executive Officer Joe Miller – Chief Financial Officer Neil Solomons – Chief Medical Officer Conference Call Participants Ed Arce – HC Wainwright Justin Kim – Oppenheimer Olivia Brayer – Cantor Fitzgerald Sahil Dhingra – RBC Operator Greetings, and welcome to Aurinia Pharmaceuticals Second Quarter 2022 Financial and Operational Results Conference Call. At this time all participants are in listen-only mode.
Investors embraced the biotech's second-quarter results.
Aurinia (AUPH) delivered earnings and revenue surprises of -13.64% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
An analyst downgraded the stock.
About Aurinia Pharmaceuticals Inc.
Description :
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
